Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03246113 : Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma
PhasePhase 1
AgesMin: 21 Years Max: 70 Years
Inclusion Criteria:

- Diagnosis of Glioblastoma requiring standard care chemoradiation of concurrent
Temozolomide and 60 Gy of radiation given over 30 treatments

- Age 21-70

- Able to give informed consent, and comply with study procedures

Exclusion Criteria:

- Meet DSM-V criteria for current major psychiatric illness, such as bipolar disorder,
major depression, active suicidal intent, or psychosis that could be exacerbated by
the administration of cannabis

- Meet DSM-V criteria for major neurological disorder, such as mild cognitive impairment
or neurodegenerative disorders (such as movement disorders, dementia), that could be
exacerbated by the administration of cannabis.

- Women who are not practicing an effective form of birth control (condoms, diaphragm,
birth control pill, IUD) or currently pregnant.

- Current (weekly) use of cannabis.

- Patients on supplemental oxygen or history of chronic obstructive pulmonary disease

- Cardiovascular Disease

- Compromised Immunity

- Patients with a history of substance use disorder other than nicotine, such an opiate
use disorder.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557